Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous cancer with challenging treatment outcomes.
• The NLRP3 inflammasome's role in AML pathogenesis is increasingly recognized but not fully understood.

Purpose of the Study:

• To investigate the role of the NLRP3 inflammasome in AML pathogenesis and survival.
• To explore the potential of targeting the NLRP3 pathway for AML therapy.

Main Methods:

• Analysis of public genome datasets for NLRP3 inflammasome gene expression in AML patients.
• CRISPR/Cas9 technology to generate NLRP3-deficient AML cells for functional studies.
• Proteomic and in vivo studies in mouse models to elucidate NLRP3's pathogenic mechanisms.

Main Results:

• Elevated NLRP3 expression correlates with reduced overall survival in AML patients.
• NLRP3 deletion or inhibition induces apoptosis and decreases AML cell survival.
• NLRP3 deficiency alters protein translation via the PERK/eIF2 pathway, impacting apoptosis.

Conclusions:

• The NLRP3/PERK/eIF2 axis is a novel driver of AML cell survival.
• Targeting NLRP3 and its downstream signaling pathways presents a potential therapeutic strategy for AML.
• Understanding the NLRP3 inflammasome's role may improve AML patient prognosis and treatment.